Company intelligence / Profile preview
IntelliGen Therapeutics
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
IntelliGen Therapeutics is a pre-clinical stage biotechnology company focused on discovering and developing novel small-molecule therapeutics for immune-mediated inflammatory diseases (IMIDs) and oncological disorders. The company leverages its expertise in targeting the Tumor Necrosis Factor (TNF) superfamily, with a particular focus on developing oral allosteric small-molecule antagonists against TNF-like ligand 1A (TL1A) and macrocyclic small-molecule inhibitors of TNF-alpha. By transitioning clinically validated biologic targets to oral small-molecule therapies, IntelliGen aims to provide patients with more accessible, convenient, and effective treatment options for conditions such as inflammatory bowel disease, ulcerative colitis, and Crohn's disease.
- Therapeutic areas
- ImmunologyOncologyGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on IntelliGen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IntelliGen Therapeutics.